Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Bliss GVS Pharma has informed that, subject to approval of shareholders in ensuing 39th Annual General Meeting and based on the recommendation of the Nomination & Remuneration Committee, the Board of Directors of the Company through circular resolution approved on June 22, 2024 have appointed Nandkumar Kashinath Chodankar (DIN: 02736718) as an Additional Director in the category of Non-Executive Independent Director of the Company for a period of 5 years with effect from June 22, 2024. The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July, 2023 are provided ‘Annexure-I’. Further, it has informed that as per the requirement of Circular No. LIST/COMP/14/2018-19 dated June 20, 2018 with respect to Enforcement of SEBI Orders regarding Appointment of Director by Listed Companies, while considering the appointment of Nandkumar Kashinath Chodankar, have been confirmed from him that, he is not debarred from holding the office of Director pursuant to any SEBI Order or any other such authority.
The above information is a part of company’s filings submitted to BSE.